Government drug price negotiations, lower list prices with lower rebate strategies, and biosimilars are examples of market developments changing rebate dynamics between plan sponsors and pharmacy benefit managers (PBMs)…
For years, pharmacy benefit managers (PBMs) have faced growing calls for reform. Now, those calls are becoming reality. Executive orders, Congressional action, federal departmental rules, and antitrust settlements are…
The pharmacy benefit landscape is in the midst of rapid change, making it increasingly difficult for plan sponsors to track, understand, and evaluate developments. To help cut through the complexity…
When evaluating pharmacy benefit repricings, it is easy to focus on headline savings. But spreadsheets alone don’t tell the full story…
Biosimilars have become an increasingly important part of modern healthcare. As “highly similar” alternatives to brand name biologic drugs…
Pharmacy benefit plans are not something you can set and forget. With the pace of change in the pharmacy benefit landscape, new challenges and opportunities can emerge at any time. That’s why ongoing engagement…
Yet another year ends. Check out our 2025 recap and insights on what might be in store for 2026…
Direct-to-consumer (DTC) or direct-to-patient (DTP) drug programs have recently gained significant momentum. This pharm-to table strategy…
October is Cooperative Month, a time to celebrate a business model that puts people before profit and empowers its members…
The popularity of alternative funding and sourcing vendors has grown as employers look for ways to reduce costs. To maintain viability, many vendors…
The pharmacy benefit landscape is anything but static. New drugs regularly enter the market, pricing structures shift, and participant needs evolve…
In our conversations with members and partners, we often hear similar questions about industry buzzwords. In this blog, we explore…